Working… Menu
Trial record 1 of 1 for:    SB11 | Age-related Macular Degeneration
Previous Study | Return to List | Next Study

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03150589
Recruitment Status : Completed
First Posted : May 12, 2017
Last Update Posted : June 26, 2020
Information provided by (Responsible Party):
Samsung Bioepis Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 24, 2019
Actual Study Completion Date : December 9, 2019
Certification/Extension First Submitted : January 28, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 29, 2021